RxDoctor Payments Data

Nicole Wharton

Physician Assistant · The Villages, FLNPI 1093107641

Payments from drug & device makers

$7,707in general payments, 2019–2025

Across 348 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$982
  • E.r. Squibb & Sons, L.L.C.$892
  • Regeneron Healthcare Solutions, Inc.$802
  • Sun Pharmaceutical Industries Inc.$792
  • Johnson & Johnson$744
  • Pfizer$697
  • plus $3K from 19 others

What the payments were for

  • Speaking & faculty fees$270%
  • Food & beverage$7,42096%
  • Education$2603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,707 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$326,821
Medicare patients
979
Services billed
6,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab21$194,981
Dupixent PenDupilumab45$167,139
Dupixent SyringeDupilumab26$96,174
Humira(Cf) PenAdalimumab12$80,028
RinvoqUpadacitinib12$73,587
OtezlaApremilast17$60,653
Metronidazole104$8,835
Doxycycline Monohydrate167$8,594
Clobetasol Propionate162$7,742
Fluorouracil63$6,387
Ketoconazole332$6,079
Tacrolimus19$3,207
Triamcinolone Acetonide213$1,906
Tretinoin15$1,537
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc49$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$982$73,58712 claims
AmgenOtezla$211$60,65317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →